TRANSGLIOMA

TO1

Strengthening research, technological development and innovation

The project in numbers
Duration:
36 months
Start date: 01.09.17
End date: 31.08.20
N. Partner: 6
 
Progress
Budget:
1.302.252,49€
Budget FERS:
1.106.914,62€

The project in numbers

Duration: 
36 months
Start / End: 
01.09.17 to 31.08.20
Project progress: 
55%
Budget: 
1302252.49€
Budget FERS: 
1106914.62€

TRANSGLIOMA

New glioblastoma therapies via a translational cross-border research platform
Priority Axis 1

Promoting innovation capacities for a more competitive area

Specific Objective: 
OS 1.1.
Investment Priority: 
PI 1b
Typology: 
Standard
Overall Objective of the Project: 

Increasing cooperation among key research institutes, universities, and companies operating in the biomedical field, in order to promote the transfer of innovative biomedical techniques in the field of oncology, with specific regard to glioblastoma, thus increasing competitiveness in the field of cancer research.

Project summary: 

The project addresses the challenges identified by the Europe 2020 Strategy for Smart Growth, by the Italy-Slovenia Program, and by the program areas’ Smart Specialisation Strategies. The aim is to increase cooperation among key actors in the field of biomedicine (research institutes, hospitals, universities, and companies), in order to promote the transfer of innovative biomedical techniques in the field of oncology, with a specific focus upon brain cancer (glioblastoma). The change entails the capitalisation of the results from the previous GLIOMA project (2007-2013), which focused upon the prognostic value of the detected biomarkers; the upgrade consists of validating these prognoses over a large number of cases, and using them to move on to the next phase, or rather the identification of new therapeutic approaches. The strengthening of this cross-border network will increase competitiveness in the fields of research and treatment. The outputs are the following: the development of an open-source software designed to analyse the data of the partners’ bio-banks, the identification of personalised pharmacological targets for patients, and the involvement of 3 research institutes, 2 hospitals, 1 SME PP, and other SMEs. This project will benefit researchers, medical doctors, students, SMEs, spin-offs and start-ups, as well as patients. The approach is based on the presence of a critical number of centres of excellence, and the transfer of the research results to the market. A cross-border approach is necessary because such a critical number, and the consequent results, can only be achieved through the involvement of subjects with specific yet different expertise. The project is innovative because it involves "precision medicine" in the identification of the genomic profile of the tumour, of the micro-environment, and of the cells derived from the patient (both glioma stem cells and glioma-associated stem cells), thus identifying new personalised pharmacological targets, with the possibility of identifying new treatments for a currently incurable disease.

Main results: 

Increased cooperation between research centres and biomedical SMEs within the program area, through a long-lasting cross-border network for the joint development of innovative biomedical techniques to treat glioblastoma, which will improve the state of knowledge and competitiveness in field of cancer care. The increase in cooperation is necessary for the project itself, which requires the scientific excellence of the research centres and universities, the technological skills of the partner company, and the institutional influence of the associated partners. Different and complementary skills are needed in order to obtain relevant scientific results, as the laboratory research must be corroborated by a vast collection of high-quality information (the biobank’s management platform) and by the analysis of the data collected on a large scale. The increase in collaboration will be facilitated by the prior experience obtained through the GLIOMA project, which involved most of the current partners and will also serve to bolster the scientific results and their social impact, since the work previously carried out on the prognostic factors of glioblastoma will be exploited and validated on a large scale, and we will then be able to move on to the fundamental therapeutic phase. The partnership is aimed at ensuring ongoing collaboration, and becoming a reference group for the research and potential treatment of glioblastoma in the cross-border region extending to the Western Balkans, Southern Europe, and beyond; this reputation and the impact of the research carried out on a global scale can only be guaranteed through this network’s continued perseverance. Furthermore, intensive technology transfer activities will ensure the exploitation of the results by external companies, thus increasing their potential for marketing, and, more generally, for innovation in the field of oncology, thereby improving the competitiveness of the cross-border area in this field.

Partner

Contenuto in fase di elaborazione

Lead Partner

Univerza v Ljubljani Medicinska fakulteta UL

Osrednjeslovenska
SLO

Project partner 1

Azienda Sanitaria Universitaria Integrata di Udine

Udine
ITA

Project partner 2

Elettra Sincrotrone Trieste S.C.p.A.

Trieste
ITA

Project partner 3

Nacionalni Institut za Biologijo

Osrednjeslovenska
SLO

Project partner 4

Biosistemika Doo

Osrednjeslovenska
SLO

Project partner 5

Azienda ULSS 3 Serenissima

Venezia
ITA

Documents

Poster Poster
Transglioma_ITA_1.pdf
( 462 bytes, published on 6 June, 2018 - 13:17 )

Objectives and Activities

Contenuto in fase di elaborazione

Contacts

Univerza v Ljubljani Medicinska fakulteta UL

00386 (0) 12418532
Kongresni trg 2, 1000 Ljubljana, Slovenija
Radovan Komel

Azienda Sanitaria Universitaria Integrata di Udine

00390432554275
Via Pozzuolo 330, 33100 Udine, Italia
Prof. Di Loreto Carla, Dr. Miran Skrap

Elettra Sincrotrone Trieste S.C.p.A.

0039 04037581
Strada Statale 14, 34149 Trieste, Italia
Paola Storici

Nacionalni Institut za Biologijo

00386 (0) 59232865
Večna pot 111, 1000 Ljubljana, Slovenija
Metka Novak

Biosistemika Doo

00386 (0) 12350520
Koprska 98, 1000 Ljubljana, Slovenija
Blaž Nemec

Azienda ULSS 3 Serenissima

0039 0412607111
Via Don Federico Tosatto 147, 30174 Venezia, Italia
Domenico Bagnara